Abstract
Sorafenib, a multikinase inhibitor of tumour-cell proliferation and angiogenesis, has been shown to have a role in the treatment of metastatic renal cell carcinoma (RCC). Xp11 translocation carcinoma is a rare subtype of RCC. We report an 18-year-old male patient with metastatic Xp11 translocation RCC who was responsive to sorafenib treatment. Six weeks after commencement of treatment with sorafenib, a CT scan of the patient showed increased central necrosis of the kidney mass and para-aortic lymph nodes as well as regression of the lung and pleural masses. The patient had a progression-free survival of 12 months, and overall survival of 15 months. The most severe adverse effects were grade 3 dermatitis and grade 3 anaemia. This case has demonstrated for the first time that sorafenib is active against Xp11 translocation RCC.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / adverse effects
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / genetics
-
Carcinoma, Renal Cell / secondary
-
Chromosomes, Human, X*
-
Disease-Free Survival
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / genetics
-
Kidney Neoplasms / pathology
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
Male
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pleural Neoplasms / drug therapy*
-
Pleural Neoplasms / genetics
-
Pleural Neoplasms / secondary
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Sorafenib
-
Time Factors
-
Tomography, X-Ray Computed
-
Translocation, Genetic*
-
Treatment Outcome
-
Young Adult
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Niacinamide
-
Sorafenib